The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory
NCT ID: NCT07164430
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
2100 participants
OBSERVATIONAL
2025-09-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What was the impact of the 2025 RSV prevention program on RSV-related hospitalisation in children under 2 years of age?
Participants won't need to do anything additional for the study as only routinely collected health information will be used to answer the research question.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory
NCT07177508
STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)
NCT07122661
Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection
NCT06993753
Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
NCT07235397
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV
NCT07279298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will use interrupted time series methodology to evaluate the impact of the 2025 RSV prevention program on RSV-related hospitalisation in children under 2 years of age. Historical data from 2022-2023 will form the pre-nirsevimab period, and 2022-2024 the pre-Abrysvo period. 2025 will form the post-intervention period.
Secondary objectives are to:
1. Evaluate the impact of the 2025 RSV prevention program on RSV-related Emergency Department (ED) presentations
2. Evaluate the impact on the reported incidence of RSV
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSV cases
Children aged under 2 years with laboratory confirmed RSV infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* laboratory confirmed RSV
Exclusion Criteria
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nicola Irwin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicola Irwin
Clinical Support Nurse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Canberra Hospital
Garran, Australian Capital Territory, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025.LRE.00223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.